1 The EIC Accelerator Project

EIC Accelerator Program Overview

The EIC Accelerator program, part of the European Innovation Council (EIC), is designed to support small and medium-sized enterprises (SMEs) and startups with innovative solutions that have the potential to disrupt markets. A key focus is on deep technology, encompassing sectors such as health, energy, and digital, among others. The program aims to bridge the gap between innovation and commercialization, helping innovative companies scale their solutions and attract private sector investment.

Funding Structure

The EIC Accelerator provides a unique funding model that combines grants and equity investments. The funding can be broken down into two main components:

Purpose of the EIC Accelerator

The EIC Accelerator plays a pivotal role in fostering innovation within the European deep-tech landscape. By providing financial support and resources, it helps startups and SMEs overcome common barriers, such as access to capital. The program encourages the development of groundbreaking technologies that can significantly impact society and the economy. It aims to create a more vibrant ecosystem where innovative companies can thrive, ultimately leading to job creation, enhanced competitiveness, and technological advancement within Europe.

Role in Scaling Companies

The EIC Accelerator not only provides financial assistance but also offers mentorship and networking opportunities. By connecting companies with experienced entrepreneurs, investors, and industry experts, the program facilitates knowledge transfer and strategic advice. This support is particularly beneficial for startups looking to navigate the complex landscape of scaling operations and entering new markets. The EIC Accelerator’s involvement enhances the credibility of recipient companies, thereby making it easier to secure additional funding from private investors and venture capitalists.

Case Study: MEDICSENSORS SL and SONOPHORESIS SMARTPATCH

MEDICSENSORS SL is a noteworthy winner of the EIC Accelerator, recognized for its innovative project, SONOPHORESIS SMARTPATCH. The project focuses on the development of a sonophoresis smart patch designed for pain-free, controllable, and wearable transdermal drug delivery.

Project Overview: SONOPHORESIS SMARTPATCH

The SONOPHORESIS SMARTPATCH aims to revolutionize how medications are delivered through the skin. Traditional methods of drug administration, such as injections or oral medications, can be painful, inconvenient, or less effective due to various factors like first-pass metabolism. The smart patch utilizes sonophoresis, a technique that employs ultrasonic waves to enhance the permeability of the skin, allowing for a more efficient and pain-free drug delivery method.

Technology Basics

The underlying technology of the SONOPHORESIS SMARTPATCH involves the application of low-frequency ultrasound waves to the skin surface. These waves create temporary openings in the skin's outer layer, facilitating the passage of therapeutic compounds directly into the bloodstream. This method not only minimizes discomfort but also allows for a more controlled release of medication over time, improving patient compliance and treatment outcomes.

The patch is designed to be user-friendly and wearable, making it suitable for various medical applications, including chronic pain management and drug delivery for conditions that require consistent medication levels. The smart patch incorporates sensors to monitor skin conditions and drug absorption rates, enabling personalized treatment adjustments.

Background and Impact

MEDICSENSORS SL, based in Spain, is at the forefront of innovation in the healthcare sector, focusing on smart medical devices that enhance patient care. The SONOPHORESIS SMARTPATCH has the potential to significantly impact the drug delivery landscape, offering a solution that aligns with modern healthcare demands for less invasive and more effective treatment methods.

By securing EIC Accelerator funding, MEDICSENSORS SL will be better positioned to refine its technology, conduct clinical trials, and accelerate market entry, ultimately contributing to improved health outcomes and enhancing the quality of life for patients. The support from the EIC Accelerator serves as a critical stepping stone for MEDICSENSORS SL, facilitating its journey from concept to commercialization in a competitive global market.

2 The Funding Rounds

MEDICSENSORS SL: Financing and Funding Events Since EIC Accelerator Win

MEDICSENSORS SL, based in Spain, is a medtech company developing non-invasive solutions for diabetes care. After winning EIC Accelerator funding at the January 11, 2023 cut-off, the company has had several notable financing milestones and funding rounds.

EIC Accelerator Funding (January 2023)

• MEDICSENSORS SL was awarded EIC Accelerator funding as part of the January 11, 2023 call. While the specific amount for each winner is not detailed in public sources for this cohort, winners typically receive grant support (up to €2.5 million) and may be eligible for equity investment from the EIC Fund (up to €15 million per project).
• The award positions recipients like MEDICSENSORS among innovative European deep-tech companies with strong scaling potential.

Previous Financing Rounds

• Prior to its EIC win, as of late 2017–2018:
• Closed a bridge financing round totaling €260,000 split over two tranches (€160K completed; second tranche expected Q2 2018).
• In total up to that point: €320K secured via two rounds.
• Recently closed an additional round of €270K at a company valuation of €2 million.
• Raised more than €240K in grants within a single year period prior to this reporting.

Other Public Funding Sources

Received support from Spain's Center for Industrial Technological Development (CDTI), specifically project IDI-20210087 focused on developing a new non-invasive smartpatch. This project was co-financed by FEDER funds but individual amounts are not specified in public records.

Company Valuation History

• As of late 2017 or early 2018: Company valued at approximately €2 million following its latest private investment round (€270K).
• No recent valuations post-EIC award have been published.

Investor Information

• Past investors include participants in bridge rounds; specific investors are not named publicly.
• Institutional backers include CDTI and European funds via grants.

Exit Events (IPO/Acquisition)

There are no records or announcements indicating an IPO, buyout, or acquisition event involving MEDICSENSORS SL since receiving the EIC Accelerator funding or in previous years.

Overview Table

Event/Funding Round	Date	Amount	Investors/Source	Company Valuation
Bridge Financing Round	~late 2017	€160K+€100K	Private investors
Private Investment Round	~early 2018	€270K	Private investors	~€2M
Grants	Pre-EIC	>€240K	CDTI/FEDER + other grants
EIC Accelerator Award	Jan/Mar '23†	Up to ~€17M†	(Grant + possible equity via EU/EIC Fund)
</em>Second tranche planned Q2 '18; \†Typical max package—actual figures undisclosed

No information is available regarding further private venture capital rounds post-EIC award nor any secondary liquidity events. The last disclosed valuation dates back to early-stage investment activity before securing major EU-level innovation awards.

Summary

Since submitting its successful Step 2 proposal on January 11th, 2023 and being selected as an EIC Accelerator winner later that year:

• MEDICSENSORS SL secured high-profile EU grant/equity backing but does not disclose individual investor names nor exact amounts received under each new round.
• Earlier financing details show modest angel/private investments and significant public grant dependency before scaling through major innovation programs.
• No evidence currently exists regarding IPOs or M&A exits since their most recent reported fundraising activities.

---

Sources

• EIC Accelerator-January 11 2023 Cut Off
• EIC Accelerator winners and statistics January 2023 – Strata.team
• Consortiums – Medicsen
• A new innovative method for diabetes treatment – CORDIS

3 The Press Releases

MEDICSENSORS SL, a Spanish company, was selected as a winner of the EIC Accelerator in January 2023 for its innovative project, Sonophoresis Smartpatch. This technology focuses on developing a pain-free, controllable, and wearable sonophoresis smart patch, which is designed to enhance drug delivery through the skin using ultrasound. The specific details of their funding, partnerships, or recent updates since receiving the EIC Accelerator award are not readily available in public releases.

The EIC Accelerator is a prestigious program under Horizon Europe that provides grants and equity investments to support game-changing innovations in Europe. The funding helps companies like MEDICSENSORS SL to scale up their technologies and bring them to the market. However, specific information about MEDICSENSORS SL's current projects, partnerships, or technological advancements since the award is not publicly detailed in available sources.

The company's website, medicsen.com, does not provide additional press releases or blog posts with updates on their progress or partnerships since receiving the EIC Accelerator funding. For more detailed insights into their activities and achievements, direct inquiries or updates on their official platforms might be necessary.

Sources:

• EIC Accelerator winners and statistics January 2023
• Latest EIC Accelerator Results
• Unveiling the Latest EIC Accelerator Results

4 The Technology Advancements

Medicsen: Advancements in Needle-Free Drug Delivery Technology

Medicsen (potentially referenced as Medicsensors SL in some sources) is a Spanish health tech company focused on developing needle-free wearable drug delivery devices. Founded following a pivotal moment involving a child’s rejection of insulin injections, the company has prioritized painless transdermal delivery using ultrasound to enhance skin permeability for macromolecules like insulin and heparin[^1^][^8^].

Current Capabilities

The core innovation is a wearable, 4x2x1 cm device that employs harmless ultrasonic waves to temporarily enlarge skin pores, enabling drug molecules up to 200 kDa to pass through. This technology addresses adherence challenges for chronic conditions like diabetes by eliminating needles and reducing discomfort. The team includes specialists in ultrasound physics, biomedical engineering, and clinical development.

Post-EIC Accelerator Funding Progress

While the specific EIC Accelerator award details for Medicsensors SL in January 2023 are not publicly documented in available sources, the company’s public updates highlight ongoing advancements:

• Technology Refinement: Continued emphasis on miniaturization and usability of their wearable device, though no explicit post-2023 technical upgrades are detailed in accessible records.
• Market Presence: Collaborative mentions with industry partners (e.g., Nemera) suggest engagement in sector discussions but lack direct evidence of customer pilots or clinical trials post-2023.
• Intellectual Property: No new patents or peer-reviewed studies are cited after 2023. Earlier documentation emphasizes their foundational approach to ultrasonic transdermal delivery.

Demonstrations and Clinical Validation

Publicly disclosed demonstrations or trials remain unreported since the EIC submission. Pre-2023 materials describe preclinical validation of pore-enhancing technology but omit recent clinical milestones.

---

Sources

• Medicsen Official Website
• Skin Drug Delivery: Dermal, Transdermal & Microneedles (ONdrugDelivery)

5 The Partnerships and Customers

MEDICSENSORS SL: Recent Developments and Partnerships

Overview of MEDICSENSORS SL

MEDICSENSORS SL, operating under the brand Medicsen, is a Spanish company focused on improving the quality of life for individuals with chronic diseases. The company is renowned for its innovative, needle-free, and wearable drug delivery device that utilizes harmless waves to increase the size of natural skin pores, allowing macromolecules like insulin and heparin to pass through the skin.

EIC Accelerator Funding

In January 2023, MEDICSENSORS SL won the EIC Accelerator funding, marking a significant milestone for the company. This funding is expected to support the development and commercialization of its groundbreaking drug delivery technology.

Partnerships and Customers

Currently, specific names of new partners or customers for MEDICSENSORS SL are not publicly disclosed. However, the company has emphasized its collaboration with various entities to advance its technology and market presence. MEDICSENSORS SL has received funding from the Center for Industrial Technological Development (CDTI) for the development of a non-invasive Smartpatch for personalized diabetes treatment, co-financed by the European Regional Development Fund (FEDER).

Nature of New Relationships

The nature of new relationships for MEDICSENSORS SL is focused on technological advancement and market expansion. These partnerships likely involve collaborations with pharmaceutical companies, medical research institutions, and possibly other technology firms to enhance the capabilities of its drug delivery systems.

Impact on Market Position and Technology Advancements

The new relationships and funding will position MEDICSENSORS SL as a leader in the wearable drug delivery market, particularly in the area of non-invasive technologies. These collaborations will help the company scale its operations, improve its technology, and reach a broader audience with its innovative products. The partnerships will also facilitate the integration of new technologies, such as advanced ultrasound systems, further enhancing the efficiency and safety of drug delivery.

Scaling and Market Expansion

By leveraging these relationships and funding, MEDICSENSORS SL is poised to expand its market presence across Europe and potentially into other regions. The company's focus on user comfort and adherence to treatment protocols aligns well with the growing demand for advanced dermatology drug delivery devices, which are increasingly preferred for their reduced pain and enhanced medication adherence features.

Sources

• Medicsen
• Medicsen - Spanish Version
• Consortiums - Medicsen
• The Global Advanced Dermatology Drug Delivery Devices Market
• Global Advanced Dermatology Drug Delivery Devices Market

6 The Hiring and Company Growth

Medicsensors SL: Team Growth and Strategic Hiring Post-EIC Accelerator Funding Medicsensors SL (appearing under the domain medicsen.com) specializes in needle-free, wearable drug delivery technology using ultrasound to enable painless transdermal macromolecule delivery. The company, founded in 2015, has positioned itself as a key innovator in advanced dermatology drug delivery devices, competing with firms like LTS Lohmann Therapie-Systeme AG and Nemera.

Team Structure and Growth Insights

• Current headcount: Specific figures are unavailable, but leadership includes CEO Eduardo Jorgensen, COO César de Mercado, CTO José Carlos Montesinos, and specialists in clinical development (Alejandro Ruiz), biomedical research (Carlos Jorgensen), and ultrasound engineering (Nuria G. Salido).
• Key growth areas: Recent emphasis on expanding technical roles such as ultrasound engineers and clinical product developers to advance their wearable device pipeline.
• Hiring status: While active hiring isn’t explicitly listed post-EIC funding (2023), the company’s inclusion in competitive market reports suggests ongoing recruitment to support R&D scaling.

Strategic Impact of New Hires

Recent additions like Julio Quirce (ultrasound physicist) and Romina Dominzain (innovation strategist) indicate a focus on enhancing technical capabilities and securing partnerships for commercialization. These roles align with Medicsen’s mission to translate its needle-free insulin delivery system into clinical adoption.

Management Stability

The founding team remains intact since 2015, with no reported leadership changes post-EIC award. Continued leadership by Eduardo Jorgensen reflects stability in executing their roadmap for CE marking and market entry.

---

Sources

• Medicsen - Core Team
• Skin Drug Delivery: Dermal, Transdermal & Microneedles Report
• Advanced Dermatology Drug Delivery Devices Market Analysis

7 The Media Features and Publications

MEDICSENSORS SL: Overview and Achievements

Company Overview

MEDICSENSORS SL, a Spanish technology start-up, specializes in developing innovative healthcare solutions. Founded in 2015, the company is known for its pioneering work in needle-free, wearable transdermal drug delivery devices, utilizing ultrasound technology to enhance drug absorption through the skin. This approach allows for the painless administration of large molecules like insulin, heparin, and other hormones, improving the quality of life for patients with chronic conditions.

Media Features and Publications

While there is limited specific information available about publications that have named MEDICSENSORS SL, the company's groundbreaking technology has likely captured attention in the medical and technological sectors. MEDICSENSORS SL has been recognized for its innovative solutions, which have the potential to revolutionize drug delivery systems.

Podcasts and Interviews

Currently, there are no specific podcasts or interviews featuring the team of MEDICSENSORS SL mentioned in the available data. However, their participation in medical and technological forums is likely given their innovative contributions.

Conference and Fair Visits, Presentations

MEDICSENSORS SL might participate in various medical technology conferences to showcase its advancements in transdermal drug delivery systems. However, specific details about their participation in conferences or fairs are not readily available in the current data.

Involvement in Events

The company's involvement in events related to medical technology and innovation is expected, given its focus on developing cutting-edge healthcare solutions. MEDICSENSORS SL's participation in such events would help in networking and showcasing its products to a broader audience.

EIC Accelerator Funding

MEDICSENSORS SL received the EIC Accelerator funding in January 2023. This recognition highlights the company's potential for growth and innovation in the European healthcare sector.

Sources

• Medicsen
• MEDICSENSORS SL Company Details
• Terms and Conditions of Medicsen
• Medicsensors Ltd.
• Scientific Research and Development Services Companies
• Transforming Medical Communications Podcast
• Medicsen Projects
• Skin Drug Delivery